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Abstract
Rationale: Infection of the lung with Pseudomonas aeruginosa results in upregulation of nitric oxide synthases (NOS) and
arginase expression, and both enzymes compete for L-arginine as substrate. Nitric oxide (NO) production may be regulated
by arginase as it controls L-arginine availability for NOS. We here studied the effect of systemic arginase inhibition on
pulmonary L-arginine metabolism in Pseudomonas pneumonia in the mouse.
Methods: Mice (C57BL/6, 8–10 weeks old, female) underwent direct tracheal instillation of Pseudomonas (PAO-1)-coated
agar beads and were treated by repeated intra-peritoneal injections of the arginase inhibitor 2(S)-amino-6-boronohexanoic
acid (ABH) or PBS until lungs were harvested on day 3 of the infection. L-arginine metabolites were quantified using liquid
chromatography-tandem mass spectrometry, NO metabolites nitrate and nitrite by Griess reagent and cytokines by ELISA.
Results: NO metabolite concentrations (48.562.9 vs. 10.962.3 mM, p,0.0001), as well as L-ornithine (29.661.7 vs
2.360.4 mM, p,0.0001), the product of arginase activity, were increased in Pseudomonas infected lungs compared to naı¨ve
controls. Concentrations of the NOS inhibitor asymmetric dimethylarginine (ADMA) were also increased (0.4460.02 vs.
0.1660.01 mM, p,0.0001). Arginase inhibition in the infected animals resulted in a significant decrease in L-ornithine
(14.661.6 mM, p,0.0001) but increase in L-arginine concentration (p,0.001), L-arginine/ADMA ratio (p,0.001), L-arginine
availability for NOS (p,0.001), and NO metabolite concentrations (67.365.7 mM, p,0.05). Arginase inhibitor treatment also
resulted in an increase in NO metabolite levels in animals following intratracheal injection of LPS (p = 0.015). Arginase
inhibition was not associated with an increase in inflammatory markers (IFN-c, IL-1b, IL-6, MIP-2, KC or TNF-a) in lung.
Concentrations of the L-ornithine-dependent polyamines putrescine, spermidine and spermine were increased in
Pseudomonas infected lungs (p,0.001, respectively) but were unaffected by ABH treatment.
Conclusions: Systemic arginase inhibition with ABH during Pseudomonas pneumonia in mice results in an increase in
pulmonary NO formation but no pro-inflammatory effect.
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Introduction
Infection of the lung with bacteria leads to increased expression
of the inducible nitric oxide synthase (iNOS or NOS2) and NO
production [1–3], as does intra-tracheal instillation of lipopoly-
saccharide (LPS) [4,5]. NO production from NOS depends on the
availability of substrate and co-factors, as well as the presence of
endogenous inhibitors including asymmetric dimethylarginine
(ADMA) [6]. In the context of lung infection with P. aeruginosa,
an opportunistic pathogen frequently causing infections in patients
with chronic lung diseases including chronic obstructive pulmo-
nary disease (COPD), bronchiectasis or cystic fibrosis (CF),
evidence suggests that relative airway NO deficiency may have
negative effects for the host. Studies in CF patients for instance
have shown that low levels of airway NO are a risk factor for
acquisition of this pathogen [7]. In addition, in a rat model of
chronic P. aeruginosa lung infection, supplementation with L-
arginine reduced the pro-inflammatory cytokine interleukin (IL)-
1b in airways, inhibited neutrophil recruitment, and ameliorated
lung tissue damage, while pharmacological inhibition of NOS in
this model significantly worsened lung damage [3].
Arginase is an enzyme that converts L-arginine to urea and L-
ornithine. The two isoforms of arginase are expressed in a number
of tissues including the lung and are thought to reduce NO
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production from NOS by limiting the availability of substrate L-
arginine [6,8,9]. Thus arginase may represent a target for
interventions aiming to increase L-arginine availability for NOS
and NO production. Inhibition of arginase in animal models of
allergic airway inflammation, for instance, resulted in anti-
inflammatory effects and abrogation of airway remodeling and
hyperresponsiveness to methacholine in these animals, presumably
by increasing L-arginine availability for NOS and increased NO
formation [10–12]. Data on whether inhibition of arginase can
increase NO production in the context of bacterial infection in-
vivo are currently lacking. We therefore studied the effects of
chronic systemic arginase inhibition on the pulmonary L-arginine
metabolism in a mouse model of chronic P. aeruginosa lung
infection.
Methods
The experiments were approved by the institutional Animal
Care Committee and were conducted in accordance with the
guidelines of the Canadian Council for Animal Care.
Mice and infection protocol
Eight to ten week old female C57BL/6 mice purchased from
Charles River Laboratories (Charles River, Oakvile, Quebec,
Canada) were housed in a pathogen-free environment and
received autoclaved food and water in the laboratory animal
services at our institution. Agarose beads embedded with
Pseudomonas aeruginosa (mPAO1) were made following a published
protocol [13] and modified by us, and beads were injected into the
airways after intubation under direct vision as previously described
[13] in anaesthetized mice (ketamine 150 mg/kg and xylazine
10 mg/kg administered intraperitoneally). A final P. aeruginosa dose
of 26106 CFU in a volume of 40–50 ml was injected into the
trachea. Infected mice were treated with a total of 4 i.p. injections
of PBS or 100 mg of the arginase inhibitor 2(S)-amino-6-
boronohexanoic acid (ABH) dissolved in 0.3 ml of PBS at 24,
48, 60 and 70 hours following the instillation of PAO-1. Body
weight was monitored daily, before and for 3 days following the
infection. At 72 hours post infection mice were anaesthetized,
blood was drawn by intracardial puncture and organs were
harvested. Uninfected not ABH treated mice were used as
controls.
A different group of animals (male BALB/c mice, 8 weeks old)
underwent an established LPS pneumonia protocol [14]. Anaes-
thetized mice were instilled with 50 mg of LPS from E. coli
O111:B4 (Sigma) and treated with i.p. injections of PBS (n = 8) or
ABH (n= 8) similar as above, immediately before, and 12, 24, 36
and 48 hrs post instillation of LPS. Lungs were harvest immedi-
ately after the last injection of ABH or LPS and processed on ice.
Lysis buffer (25 mM Tris-HCl, pH 7.4, 1% TritonX100, 10%
glycerol) containing protease inhibitors (Complete, Mini, EDTA-
free plus 2 mM EDTA, Roche Applied Science) was added
(2.5 ml/g lung). Tissue was homogenized using high-speed
homogenizer (Polytron PT 1200E, Kinematica, Switzerland) for
1 min 3 times. Samples were then centrifuged (14000 rpm, 4uC)
for 20 min, supernatants aliquoted and stored at 280uC until
further analyses.
Liquid chromatography-tandem mass spectrometry (LC/MS/
MS) to measure L-arginine, L-ornithine, L-citrulline, ADMA and
the L-ornithine derived polyamines putrescine, spermidine and
spermine was performed in supernatant of organ homogenates as
previously described [15,16]. NO metabolites in plasma and in
lung homogenates from the LPS pneumonia model were
quantified with help of a chemiluminescence analyzer (Eco Physics
CLD 88 sp, Du¨rnten, Switzerland), while Griess reagent (Cayman,
Ann Arbor, MI) was used for nitrate and nitrite measurements in
lung homogenates of animals infected with Pseudomonas. Arginase
activity was measured by conversion of L-arginine to ornithine in-
vitro, as previously described [17]. A multi-analyte panel enzyme-
linked immunosorbent assay (ELISA) was used to determine the
concentrations of interferon-c (IFN-c), interleukin-1 beta (IL-1b),
IL-6, macrophage inflammatory protein 2 (MIP-2), keratinocyte
chemoattractant (KC), and tumor necrosis factor-alpha (TNF-a) in
supernatant of lung homogenates (Millipore, Billerica, MA, USA).
All results are expressed as the mean 6 standard error of the
mean (SEM). Binary comparisons were made with two-tailed
student’s t-test or Mann-Whitney test, where appropriate.
Comparisons of three groups were performed by one-way
ANOVA with Turkey’s multiple comparison or Kruskal-Wallis
test with Dunn’s multiple comparison post hoc test, where
appropriate. P-values,0.05 were considered statistically signifi-
cant. Statistical analyses were conducted using GraphPad Prism
4.0c (Graphpad Software Inc., La Jolla, CA USA).
Results
P. aeruginosa lung infection resulted in significant weight loss but
no mortality in animals. Weight loss following infection did not
differ significantly (ANOVA) between ABH and PBS treated mice
on day 1 (5.960.9 vs. 5.460.4%), day 2 (10.160.9 vs. 9.461.2%)
or day 3 (7.561.7 vs. 6.761.9%). There was no difference in lung
wet weights between ABH and PBS treated infected mice
(0.16760.017 g vs. 0.19360.007 g, p= 0.244).
Pseudomonas infection resulted in a significant increase in L-
arginine concentrations (28.461.4 vs 17.560.7 mM, p,0.0001)
and a more pronounced increase in L-ornithine (29.661.7 vs
2.360.4 mM, p,0.0001) in lung homogenates of infected mice
compared to non-infected controls. Consequently, the L-arginine/
L-ornithine ratio, an index of L-arginine availability for intracel-
lular NOS [18,19], was significantly reduced by P. aeruginosa
infection (Figure 1). Treatment with the arginase inhibitor ABH,
resulted in a significant decrease in L-ornithine (14.661.6 mM,
p,0.0001), the product of arginase activity, but increase in its
precursor L-arginine (38.962.2 mM, p= 0.001). The L-arginine/
L-ornithine ratio increased significantly with ABH treatment but
did not normalize (Figure 1). L-citrulline concentrations were
higher in the infected animals compared to non-infected controls
(47.264.1 vs. 6.360.4 mM, p,0.0001) but not different in PBS vs
ABH treated animals (49.569.2 mM).
P. aeruginosa infection also resulted in a significant increase in the
concentration of the competitive NOS inhibitor ADMA
(0.4460.02 vs. 0.1660.01 mM, p,0.0001) and a decrease in the
L-arginine/ADMA ratio, an index of NOS impairment. ABH
treatment did not affect ADMA concentrations in the lung but
restored the L-arginine/ADMA ratio to normal (Figure 2).
Plasma NOx concentrations were higher in Pseudomonas infected
PBS treated animals than controls (41.866.1 vs. 27.562.1 mM,
p= 0.02) but not different from ABH treated animals
(43.967.5 mM). NOx (nitrate+nitrite) concentrations were signif-
icantly increased in infected lungs compared to controls (48.562.9
vs. 10.962.3 mM, p,0.0001) and further increased with ABH
treatment (67.365.7 mM, p= 0.01) (Figure 3). A significant
increase in lung NO metabolite concentrations following arginase
inhibition was also seen in the LPS pneumonia model (ABH vs.
PBS: 26.065.7 vs. 10.160.8 mM, p= 0.01) (Figure 3).
NOx concentrations in liver homogenates were not different
between the ABH or PBS treatment groups (23.163.2 vs.
24.165.2 mM) but ABH resulted in a significant increase in
Arginase Inhibition in Pseudomonas Pneumonia
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NOx in kidney homogenates (25.563.7 vs. 7.262.1 mM,
p= 0.001). As arginase 1 is the predominant isoform expressed
in liver while arginase 2 is the predominant arginase isoform
expressed in kidney, the differences in NOx concentration
between the two organs is suggestive of arginase 2 specificity of
ABH.
Arginase activity measured in lung homogenates in-vitro
confirmed an increase in infected mice (48.8620.8 vs.
1562.3 mU/mg protein, p,0.005). The expression of both
arginase isoforms was increased in lung of infected mice using
Western blot analysis (data not shown). Concentrations of the L-
ornithine derived polyamines putrescine, spermidine and spermine
were significantly higher in infected mice but not different between
PBS and ABH treated animals (Table 1). Cytokine concentrations
for the three groups are shown in Table 2. ABH treatment did not
have an effect on cytokine concentrations.
Discussion
We here show that Pseudomonas infection of the lung resulted in a
significant increase in lung tissue L-ornithine, the product of
arginase activity. While there was also an increase in L-arginine
concentration in the lung following infection, the availability of L-
arginine for NOS, expressed as L-arginine/ornithine ratio, was
lower in infected mice than in non-infected controls. In addition,
we observed an increase in the concentration of the competitive
NOS inhibitor ADMA in infected lungs. Systemic application of
an arginase inhibitor resulted in increased L-arginine availability
Figure 1. Concentrations of the amino acids L-ornithine and L-
arginine in mouse lung homogenates of untreated (naı¨ve)
control as well as Pseudomonas infected mice treated with PBS
or the arginase inhibitor 2(S)-amino-6-boronohexanoic acid
(ABH). L-ornithine, the product of arginase activity, as well as L-
arginine was significantly lower in naı¨ve, compared to infected lungs
(*: p,0.0001, ANOVA, respectively). ABH treatment resulted in a
significant decrease in L-ornithine but increase in L-arginine concen-
tration (p,0.001, t-test, respectively). The L-arginine/L-ornithine ratio,
which can be used as an index of L-arginine availability for intracellular
NOS, was reduced in infected lungs (*: p,0.0001, ANOVA) but
improved in the ABH treatment group (p,0.001, t-test).
doi:10.1371/journal.pone.0090232.g001
Figure 2. Concentrations of the nitric oxide synthase inhibitor
asymmetric dimethylarginine (ADMA) in mouse lung homog-
enates of untreated (naı¨ve) control as well as Pseudomonas
infected mice treated with PBS or the arginase inhibitor
2(S)-amino-6-boronohexanoic acid (ABH). ADMA was significantly
lower in naı¨ve compared to Pseudomonas infected lungs
(*: p = 0.0001, Kruskal-Wallis test). The L-arginine/ADMA ratio, which
can be used as an index of NOS impairment, was significantly reduced
in infected lungs (*: p,0.0001, ANOVA). Treatment with ABH did not
change ADMA concentrations but resulted in normalization of the L-
arginine/ADMA ratio. (p,0.001, t-test).
doi:10.1371/journal.pone.0090232.g002
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for NOS and increased NO production. Increased NO production
induced by arginase inhibition was not associated with an increase
in pro-inflammatory cytokines in P. aeruginosa infected animals.
Arginase and NOS both compete for L-arginine as substrate
and an important role of arginase is thought to be the regulation of
NO production by limiting L-arginine availability for NOS
[6,8,9]. While excessive NO production may have negative effects
on inflammation, it is also possible that substrate limitation for
NOS results in deleterious effects due to uncoupling of the enzyme
resulting in superoxide radical formation [3,20–22]. An example
for the importance of the arginase/NOS balance for host/
pathogen interactions is Campylobacter pylori, which induces arginase
activity as a strategy to limit L-arginine availability for host NOS
in order to reduce NO-mediated host defense and facilitate
persistent gastric mucosal infection [23]. Pseudomonas is highly
sensitive to NO- and nitrite-mediated killing, and therefore,
limitation of NO production during infections with this bacterium
may promote infection [24]. We have recently shown using stable
isotopes, that infection of the mouse lung with P. aeruginosa resulted
in a significant increase in the expression and activity of NOS 2
but also arginase 1 and arginase 2 [25]. In the current study we
demonstrated that systemic arginase inhibition enhances pulmo-
nary NO production using an established model of P. aeruginosa
lung infection in the mouse. The observed changes in NO
production in the infected and ABH treated animals were not
caused by effects of the arginase inhibitor on Pseudomonas, as similar
increases in NO following the administration of ABH were also
seen in animals with intratracheal LPS instillation. Gender
disparity exists in certain aspects of the nitric oxide pathway
[26–29], and it is therefore worth mentioning that the infected
animals in our experiments were females while the LPS treated
were male mice. As arginase inhibition resulted in increases in NO
production in both groups, it can be speculated that the effect of
ABH on pulmonary NO production in the mouse is gender
independent. However, further studies will be needed to assess
whether treatment with arginase inhibitors may result in different
physiological responses in males and females.
Our results also showed that infection of the lung resulted in a
significant increase in the concentration of the competitive NOS
inhibitor ADMA and a decrease in L-arginine/ADMA ratio (NOS
substrate/inhibitor) an index reflecting NOS impairment. Effects
of ADMA in the context of respiratory infections with Pseudomonas
were previously studied using human nasal epithelial cells. Pre-
incubation with ADMA significantly reduced Pseudomonas-induced
epithelial damage, loss of ciliated cells and bacterial adherence to
the cultured respiratory mucosa in-vitro [30]. While these data
Figure 3. Nitric oxide metabolite (NOx) concentrations in mouse lung homogenates of untreated (naı¨ve) control as well as
Pseudomonas infected mice treated with PBS or the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH). Concentrations were
significantly different between groups (p,0.0001, ANOVA). NOx levels in lung were lower in naı¨ve compared to Pseudomonas infected and PBS
treated mice (*: p,0.001, Mann-Whitney test). ABH treatment resulted in a significant increase in ABH vs. PBS treated animals (p,0.05, Mann-Whitney
test). A similar increase in lung NOx after ABH treatment was seen in mice after intratracheal instillation of lipopolysaccharide (LPS) (p = 0.015, t-test).
doi:10.1371/journal.pone.0090232.g003
Table 1. Concentrations (mmol/L) of the L-ornithine derived
polyamines putrescine, spermidine and spermine in lung
homogenates of naı¨ve control and Pseudomonas infected
mice treated with PBS or arginase inhibitor ABH.
Putrescine Spermidine Spermine
Control 4.961.2 * 4.061.2 * 2.660.7 *
Pseudomonas
PBS 34.262.4 39.662.3 13.660.8
ABH 28.762.9 37.563.7 12.560.8
* Concentrations were significantly different between groups (p,0.001,
ANOVA). All three polyamines were lower in controls compared to infected
animals but not different between PBS or ABH treatment group (n = 6–8/
group).
doi:10.1371/journal.pone.0090232.t001
Table 2. Cytokine concentrations (ng/g) in lung
homogenates of naı¨ve control and Pseudomonas infected
mice treated with PBS or arginase inhibitor ABH.
P. aeruginosa
Control (n =6) PBS (n =14) ABH (n=15)
IFN-c 0.0460.01 * 3.5060.83 2.5460.52
IL-1b 8.5460.96 15.5163.02 12.2662.37
IL-6 9.9760.51 * 52.2765.67 65.09612.1
MIP-2 0.1560.01 * 59.4667.30 44.2963.67
KC 4.5261.43 * 31.8465.90 29.2863.58
TNF-a 0.0560.01 * 7.6161.41 5.4860.83
Concentrations were significantly different between groups (p,0.001, Kruskal-
Wallis test). All cytokines with the exception of IL-1b were lower in controls
compared to infected animals not different between PBS and ABH treated
animals.
doi:10.1371/journal.pone.0090232.t002
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provided evidence that ADMA was associated with beneficial
effects, it was unclear in that study whether the observed effects of
ADMA were direct or mediated through inhibition of NOS, as
ADMA did not cause a significant change in nitrite concentration
in the culture medium [30]. In our experiments ABH treatment
did not result in a change in ADMA concentration in the infected
lungs, but normalized the ratio of L-arginine/ADMA with a
concomitant increase in NO production.
Dosing of the arginase inhibitor was based on previous
publications on systemic use of ABH in rodents [31,32]. The
half-life of ABH in C57BL/6 mice was previously reported to be
approximately 8 hours [33]. There was no evidence that repeated
systemic application of the arginase inhibitor was harmful to the
animals. Although Pseudomonas resulted in significant weight loss in
the animals on day 1 and day 2 of the infection, there were no
differences in weight loss between the groups of ABH or PBS
treated animals. There was also no significant difference in
cytokine concentrations in lung homogenates when comparing
ABH and PBS treated mice, suggesting that neither ABH nor the
increase in NO production in the lung had a pro-inflammatory
effect. Previous work has shown that mice deficient for NOS2 had
impaired clearance of Pseudomonas from the lung 18 h after
infection [34]. The present study focused on the effect of arginase
inhibition on NO production; whether the increase in NO
formation would lead to altered defense against Pseudomonas was
not assessed, but should be investigated in future studies.
L-ornithine, the product of arginase activity, is substrate for
collagen formation but also for polyamine biosynthesis. Poly-
amines are important in cell repair and also act as NOS inhibitors
[6,9,16]. Arginase activity and polyamine levels are significantly
increased in models of asthma and in the guinea pig for instance,
the increase in putrscine was prevented by pharmacological
blockade of arginase [11]. In our experiments, Pseudomonas
infection also resulted in a significant increase in polyamine
concentrations in the lung. Arginase inhibition reduced L-
ornithine formation by approximately 50% but there was no
effect on polyamine concentrations in the lung. This could likely
be due to the fact that ornithine availability for ornithine
decarboxylase (ODC), the first and rate-limiting step in L-
ornithine dependent polyamine biosynthesis [35] remained
sufficient for polyamine production.
An alternative strategy to increase concentration and availabil-
ity of L-arginine for NOS is supplementation of its substrate. A
previous study using a chronic model of Pseudomonas infection of
the lung in rats had shown that L-arginine given in drinking water
resulted in lower IL-1b concentrations in BAL fluid in the L-
arginine treated compared to the untreated group, whereas VEGF
was increased. L-arginine supplementation has the potential
disadvantage of providing substrate for NOS but also arginase
enzymatic activity, which may result in unwanted effects of L-
ornithine derived metabolites. For instance, generation of sperm-
ine by ODC inhibits iNOS translation and NO-mediated H.
pylori killing [36,37]. Studies in humans with CF or asthma, both
conditions associated with increased arginase activity and relative
NO deficiency, have shown that the effect of systemic L-arginine
supplementation on pulmonary NO formation is moderate and
limited by increased formation of the NOS inhibitor ADMA, a
product of protein degradation [38,39]. Ultimately, one approach
does not exclude the other and the combination of both may have
the highest likelihood of addressing the relative NO deficiency in
P. aeruginosa infection.
In conclusion systemic ABH used in the early phase of acute P.
aeruginosa lung infection at doses effective to significantly reduce
arginase activity in the lung result in increased pulmonary NO
production. The role of pharmacological inhibition of arginase for
treatment of lung infections deserves further investigation.
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